IMMUNOCELLULAR THERAPEUTICS LTD |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
Financials (USD)
| Sales 2020 | - | Sales 2021 | - | Capitalization | 20.69M |
|---|---|---|---|---|---|
| Net income 2020 | -1M | Net income 2021 | -5M | EV / Sales 2020 * | - |
| Net cash position 2020 | 263K | Net Debt 2021 | 1.33M | EV / Sales 2021 | - |
| P/E ratio 2020 * |
-
| P/E ratio 2021 |
-3.82
x | Employees | - |
| Yield 2020 * |
-
| Yield 2021 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Eli Goldberger
FOU | Founder | 34 | - |
| Chief Executive Officer | 68 | 21-11-30 | |
Wayne Danson
DFI | Director of Finance/CFO | 70 | 21-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Frank Douglas
BRD | Director/Board Member | 80 | 22-03-31 |
| Chief Executive Officer | 68 | 21-11-30 | |
Julie Kampf
BRD | Director/Board Member | 62 | 22-03-31 |
ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is developing immune-based therapies for the treatment of cancers. The Company's cancer immunotherapies target cancer stem cells (CSCs), which are the drivers of tumor growth and disease recurrence. Its product candidate is ICT-107, which is in phase III testing. In addition, the Company also has a portfolio of other potential therapeutic immunotherapies using a range of approaches to treat cancer. Its other product candidates are ICT-140 and ICT-121. ICT-107 is a dendritic cell (DC) vaccine for the treatment of newly diagnosed glioblastoma multiforme (GBM), a type of brain cancer. ICT-140 is a DC vaccine that targets over seven tumor-associated antigens expressed on ovarian cancer cells. It is developing ICT-121, a dendritic cell (DC)-based vaccine targeting CD133+ CSCs for the treatment of recurrent GBM and other solid tumor cancers, including ovarian, pancreatic and breast cancers.
Sector
-
